A promising challenge, both for incoming therapies and for knowledge of tumor(s) biology
Myeloma Remission Is Produced by Re-Engineered Measles Virus in Early Studies — Physician’s First Watch
Myeloma Remission Is Produced by Re-Engineered Measles Virus in Early Studies
By Joe Elia
Two patients with disseminated, treatment-resistant multiple myeloma have shown promising responses to therapy with a re-engineered measles virus, according to a Mayo Clinic Proceedings study that's gotten a lot of press attention.
The patients both received large doses of a measles virus strain used to make vaccine. The virus was further changed to let researchers track its entry into myeloma cells, which carry a receptor to which the virus readily attaches. Infection causes the destruction of the target cells. One patient had a forehead lesion that shrank dramatically; she had a complete remission of all metastases lasting 9 months. The other patient showed improvement in only some lesions.
An editorialist writes that the work provides "compelling evidence that a single infusion of an [oncolytic virus] can lead to complete systemic antitumor responses, even in patients with advanced cancer." The lead researcher is similarly enthusiastic in a video presentation.